Idelvion market forecast points to growth in home treatment and personalized care

The Idelvion market is projected to expand as hemophilia B care shifts toward longer-acting therapies, home infusion, and more personalized treatment plans. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Idelvion is positioned as a treatment option that can reduce infusion frequency for people with hemophilia B. - The market outlook matters because demand is being shaped by home-based care, preventive treatment, and broader access to specialized hemophilia services. - The report ties market growth to real-world care changes that can improve convenience, quality of life, and bleeding control for patients.

What happened: - The Business Research Company published an Idelvion market forecast report focused on segment analysis and strategic industry insights. - The report says the Idelvion market is set for notable growth through the forecast period. - North America held the largest share of the Idelvion market in 2025. - Asia-Pacific is projected to be the fastest-growing region through the forecast period. - The regional analysis also covers Western Europe, Eastern Europe, South America, the Middle East, and Africa.

The details: - Idelvion, or albutrepenonacog alfa, is a recombinant extended half-life factor IX replacement therapy for treating and preventing bleeding episodes in hemophilia B. - The therapy is designed to provide sustained clotting factor activity and reduce the number of infusions needed. - The report says historical growth was driven by frequent bleeding in hemophilia B patients, limits of standard half-life clotting factors, early use of recombinant factor IX therapies, efforts to prevent joint damage, and the expansion of specialized hemophilia treatment centers. - Forecast-period growth is expected to come from broader use of long-acting clotting factors, more home infusion access, expanded care for pediatric hemophilia patients, supportive reimbursement for prophylactic treatment, and continued innovation in recombinant clotting factors. - The report identifies wider adoption of extended half-life factor therapies, a shift toward preventive hemophilia management, patient preference for fewer infusions, stronger focus on quality of life, and growth in home-based treatment programs as key trends. - The report says home-based treatment is helping the market by giving patients more control over schedules, fewer facility visits, and greater independence. - In June 2025, Harmony Healthcare IT data showed 62% of Americans had used telehealth services, and 77% viewed telehealth as the future of healthcare. - The report says personalized medicine is another growth driver because it supports tailored treatment plans and dosing strategies for hemophilia B patients. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 novel personalized therapies for rare diseases in 2023, up from six in 2022. - The report says stronger healthcare infrastructure supports availability and administration of Idelvion. - In May 2023, the UK Department of Health and Social Care announced more than $25.33 billion, or £20 billion, in investment for the New Hospital Programme to build 40 new hospitals across England by 2030.

Between the lines: - The market story is less about a single drug and more about the broader shift in hemophilia B care toward long-acting, self-managed, and prevention-focused treatment. - Home infusion and telehealth adoption suggest patients and providers are moving toward care models that reduce dependence on frequent clinic visits. - The report’s regional split points to mature demand in North America and faster expansion potential in markets where healthcare access is still improving. - The added strategic tools in the 2026 report, including TAM analysis, scoring matrices, dashboards, and hotspot infographics, signal a stronger focus on investment and planning use cases.

What's next: - Wider adoption of extended half-life factor therapies is expected to continue shaping demand. - Improved reimbursement and expanding pediatric treatment options could support additional market growth. - Better healthcare infrastructure in emerging markets may help widen access to Idelvion and similar therapies. - The Business Research Company says its 2026 market reports now include expanded strategic intelligence, updated graphics, and new analysis tools. - More information is available in the full report and a free sample.